Katie Kosko

DocwireNews

Circulating tumor DNA (ctDNA) may help guide oncologists in determining which patients with inoperable stage III non-small cell lung cancer (NSCLC) need to receive immunotherapy for a longer amount of time, according to study findings published in the Journal of Thoracic Oncology.The current standard of care for this patient population consists of chemoradiotherapy (CRT) followed by 1 year of checkpoint inhibitor (CPI) therapy.To determine the optimal duration of consolidation CPI, the team of researchers led by Soyeong Jun, PhD, of the Stanford Cancer Institute, reviewed the relationship between minimal residual disease (MRD) determined by ctDNA and clinical outcomes in patients with NSCLC. They used plasma samples from patients (n=105) enrolled in the phase II BTCRC LUN 16-081 trial (NCT03285321). The samples were collected after completion of CRT, prior to day 1 of the second cycle (C2D1) of CPI, and at the end of up to 6 months of treatment.The researchers used ctDNA levels from each time point and evaluated those with clinical outcomes in patients with unresectable locally advanced disease.Study findings showed that the detection of ctDNA predicted significantly inferior progression-free survival (PFS) after each of the 3 periods. Following the completion of CRT, the 24-month PFS was 29% in patients where ctDNA MRD was detected compared with 65% of patients without it present. Furthermore, prior to C2D1 of CPI PFS was 0% versus 72% at 24 months, respectively. The 24-month PFS rate was 15% versus 67% at the end of CPI, respectively.Improved survival outcomes were seen in patients with NSCLC who had decreasing or undetectable ctDNA levels after 1 cycle of CPI compared with patients with increasing ctDNA levels (24-month PFS 72% vs 0%).All patients with increasing ctDNA levels at C2D1 saw progression of disease within 12 months of starting CPI.&ldquo;Detection of ctDNA before, during, or after 6 months of consolidation CPI is strongly associated with inferior outcomes,&rdquo; the researchers said. The researchers added that this ctDNA MRD analysis may allow for a more personalized approach to the duration of consolidation immunotherapy treatment.Source: <a href="https://pubmed.ncbi.nlm.nih.gov/38971369/" target="_blank" rel="noopener">Journal of Thoracic Oncology</a>

Bradley Marder, MD

Joel M. Topf, MD, FACP

Gout Studies: Transplant Waitlisting and Bone Erosion

NKF Spring Clinical Meetings 2025

Jayme Locke, MD, MPH

The Promise of Xenotransplantation

Leah Lawrence

Real-World Data Backs Invasive DFS as Surrogate Endpoint for OS in EBC

HR Breast Cancer

Latest News

Study Investigates How ctDNA May Help Personalize Immunotherapy Treatment for Inoperable NSCLC

Non-Small Cell Lung Cancer

Circulating tumor DNA (ctDNA) may help guide oncologists in determining which patients with inoperable stage III non-small cell lung cancer (NSCLC) need to receive immunotherapy.

Circulating Tumor DNA Can Help Personalize Immunotherapy Treatment for Inoperable NSCLC

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe